Avidity Biosciences gains FDA clearance for RNA-based therapies targeting rare diseases

Avidity Biosciences has received FDA clearance for its RNA-based genetic therapies, marking a significant step in its development. The company utilizes its Antibody Oligonucleotide Conjugates technology to target rare diseases. Since May 2024, Avidity's stock has increased by about 20.3%. This growth reflects investor interest in the company's advancements in genetic therapies. The FDA clearance and positive data position Avidity as a potential leader in the field of RNA therapies, differentiating it from previous developments in the industry.